期刊文献+

乳腺癌TUSC1基因启动子的甲基化及其蛋白表达的相关性 被引量:1

Promoter Methylation and Expression of TUSC1 Gene in Breast Cancer
下载PDF
导出
摘要 为探讨乳腺癌中TUSC1基因启动子甲基化及其与蛋白表达的相关性。运用甲基化特异性聚合酶链反应及Western blot检测65例浸润性乳腺癌及其对应的癌旁组织中启动子甲基化及蛋白的表达。癌旁组织均未出现TUSC1基因启动子的甲基化,对应的乳腺癌组织中61.5%出现甲基化。癌旁组织TUSC1蛋白均表达,对应的乳腺癌组织29.2%出现蛋白表达。并且甲基化发生率与蛋白表达均与TNM分期及淋巴结转移有关(P<0.05)。TUSC1基因启动子甲基化是基因失活的重要机制之一,与乳腺癌的发生及发展有关。 To study the relationship between status of methylation of TUSC 1 gene promoter and its protein in breast cancer . Methylation‐specific PCR and Western blot were applied respectively to examine the methylation of TUSC 1 gene promoter and its mRNA expression of 65 samples of invasive breast cancer and their matched adjacent non‐cancerous tissues .The results revealed that there was no methylation of TUSC1 gene promoter in adjacent non‐cancerous tissues ,while in the breast cancer tissues , the hyper‐methylation rate was 61 .5% . The result of Western blot revealed that the positive expression rate of TUSC1 protein was 100% in adjacent non‐cancerous tissues and 29 .2% in breast cancer tissues .In additional ,methylation of TUSC1 gene promoter and protein expression were related to the tumor TNM stage and lymph node metastasis (P〈 0 .05) .Methylation of promoter might be one of the important mechanisms of inactivation of TUSC 1 gene ,and might play an important role in carcinogenesis and progression of breast cancer .
出处 《医学与哲学(B)》 2015年第3期74-76,共3页 Medicine & Philosophy(B)
关键词 乳腺癌 甲基化 肿瘤抑制因子候选基因1 breast cancer methylation tumor suppressor candidate 1 (TUSC1)
  • 相关文献

参考文献8

  • 1孟翠丽,郭睿,齐凤杰,申菲菲.PTEN、p53和BAG-1在三阴乳腺癌中的表达及意义[J].医学与哲学(B),2014,35(10):71-73. 被引量:12
  • 2白璐,高志安.乳腺癌中4.1N蛋白和E-cadherin蛋白表达的临床意义[J].医学与哲学(B),2014,35(4):73-76. 被引量:14
  • 3Kanda M, Shimizu D, Nomoto S, et al. Clinical significance of ex pression and epigenetic profiling of TUSC1 in gastric cancer[J]. J Surg Oncol, 2014,110 (2) : 136-- 144. 被引量:1
  • 4Shimizu D, Kanda M, Nomoto S, et al. Identification of intragenic methylation in the TUSC1 gene as a novel prognostic marker of hepatocellular carcinoma[J]. Oncol Rep,2014,31(3):1305--1313. 被引量:1
  • 5Conway K, Edmiston S N,May R, et al. DNA methylation profiling in the Carolina Breast Cancer Study defines cancer subclasses diffe- ring in clinicopathologic characteristics and survival [J]. Breast Cancer Res,2014,16(5) :450. 被引量:1
  • 6Atalay C. Epigenetics in breast cancer[J]. Exp Oncol, 2013,35 (4) : 246--249. 被引量:1
  • 7Sheyu L, Hui L,Junyu Z, et al. Promoter met hylation assay of SASH1 gene in breast eancer[J].J BUON,2013,18(4):891-898. 被引量:1
  • 8Shan Z,Shakoori A,Bodaghi S,et a[. TUSC1 ,a putative tumor sup- pressor gene,reduces tumor cell growth in vitro and tumor growth in vivo[J]. PLuS One,2013,8(6):e66114. 被引量:1

二级参考文献20

  • 1Bardia A,Baselga J.Neoadjuvant therapy as a platform for drug development and approval in breast cancer[J].Clin Cancer Res,2013,19(23):6360-6370. 被引量:1
  • 2Chen Y J,Yeh M H,Yu M C,et al.Lapatinib induced NFkappa B activation sensitizes triple-negative breast cancer cells to proteasome inhibitors[J].Breast Cancer Res,2013,15 (6):R108. 被引量:1
  • 3Rakha E A,El Sayed M E,Green A R,et al.Prognostic markers in triple-negative breast cancer[J].Cancer,2007,109(1):25-32. 被引量:1
  • 4Wang L,Zhang Q,Zhang J,et al.PI3K pathway activation results in low efficacy of both trastuzumab and lapatinib[J].BMC Cancer,2011,15(11):248-257. 被引量:1
  • 5Jones N,Bonnet F,Sfar S,et al.Comprehensive analysis of PTEN status in breast cardnomas[J].Int J Cancer,2013,133(2):323-334. 被引量:1
  • 6Inanc M,Ozkan M,Karaca H,et al.Cytokeratin 5/6,oMet expressions,and PTEN loss prognostic indicators in triple negative breast cancer[J].Med Oncol,2014,31 (1):801. 被引量:1
  • 7Perez E A,Dueck A C,McCullough A E,et al.Impact of PTEN protein expression on benefit from adjuvant trastuzumab in earlystage human epidermal growth factor receptor 2 positive breast cancer in the North Central Cancer Treatment Group N9831 trial[J].J ClinOncol,2013,31(17):2115-2122. 被引量:1
  • 8Tanic N,Milovanovic Z,Tanie N,et al.The impact of PTEN tumor suppressor gene on acquiring resistance to tamoxifen treatment in breast cancer patients[J].Cancer Biol Ther,2012,13(12):1165-1174. 被引量:1
  • 9Alsner J,Jensen V,Kyndi M,et al.A comparison between p53 accumulation determined by immunohistochemistry and Tp53 mutations as prognostic variables in tumors from breast cancer patients[J].Acta Oncol,2008,47(4):600-607. 被引量:1
  • 10Fernandez-Cuesta L,Anaganti S,Hainaut P,et al.Estrogen levels act as a rheostat on p53 levels and modulate p53 dependent respon ses in breast cancer cell lines[J].Breast Cancer Res Treat,2011,125(1):35-42. 被引量:1

共引文献22

同被引文献4

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部